Phase 1 · NCT06003465
A Research Study Looking at Similarity Between LY3437943 Versions for Different Injection Devices
A Relative Bioavailability Study to Compare the Pharmacokinetics of LY3437943 Administered Subcutaneously by a Test Device (Test Formulation) Versus Reference Device (Reference Formulation) in Healthy Participants
CompletedVerified
Registry record
Trial details
- Trial
- A Research Study Looking at Similarity Between LY3437943 Versions for Different Injection Devices
- ClinicalTrials.gov ID
- NCT06003465
- Indication
- Healthy
- Phase
- Phase 1
- Study type
- Interventional
- Sponsor
- Eli Lilly and Company
- Enrolment
- 57
- Status
- Completed
- Interventions
- Drug: LY3437943; Device: Test; Device: Reference
- Comparator
- Not reported
- Eligible ages
- 18 Years – 70 Years
- Locations
- 3 sites · United States
- Study start
- 29 Aug 2023
- Primary completion
- 8 Feb 2024
- Study completion
- 8 Feb 2024
Verification
- Last verified
- 4 Sept 2026
- Source
- ClinicalTrials.gov
- Registry last updated
- 29 Mar 2024
Endpoints
Primary
Pharmacokinetics (PK): Maximum Concentration (Cmax) of LY3437943; PK: Area Under the Plasma Concentration Versus Time Curve from Zero to T, Last Time Point (AUC[0-tlast]) of LY3437943; PK: Area Under the Plasma Concentration Versus Time Curve From Zero to Infinity (AUC[0-∞]) of LY3437943